

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

06 Jun 2026

### Clinical trial Comparison of intravenous dexmedetomidine and intravenous Apotel and combined of those (intravenous Apodex) on postoperative emergence agitation & pain after Adenotonsilectomy with Sevofloran in children

#### Protocol summary

##### Summary

(1) Objectives: Evaluation of the effects of intravenous dexmedetomidine and intravenous Apotel and combined of those (intravenous Apodex) on postoperative emergence agitation & pain after adenotonsilectomy in children (2) Design: randomized, double blind controlled with placebo. (3) Setting and conduct: After set up monitoring & fixation of venous catheter & infusion of serum crystalloid, all patients will be received 0.5 mg/kg dexamethazone, 1 µg/kg fentanyl, 0.02 mg/kg atropine as premedication. subsequently induction of anesthesia will be applied with 2 mg/kg propofol & 1 mg/kg succinylcolin, then patients will be intubated. maintenance of anesthesia until to the end of surgery will be continued with combination of 50% oxygen, 50% nitrous oxide, and 2-3% of sevoflurane concentration. (4) Participants including major eligibility criteria. Inclusion criteria: take Informed consent from parents to enter the study; patients between 2-12 old age candidate for :Adenotonsilectomy; Physical status 1 and 2 classification of "American Society of Anesthesiologists" (ASA). Exclusion criteria: History of any cardiac, kidney, hepatic, or neurologic (convulsion) disease; Respiratory disease (Asthma or respiratory allergy); History of allergic reaction to the study drugs; History of upper airway infection in the last 4 weeks; use of any type of sedative drugs at the night before surgery; evidence of severe obstructive sleep apnea (OSA) Sample size: 132 person. (5) Intervention: Patients will be received 15 mg/kg Apotel in 50 ml normal saline in group A, 1 mcg/kg dexmedetomidine in 50 ml normal saline in group D, 10 mg/kg Apotel and 0.3 mcg/kg dexmedetomidine in 50 ml normal saline in group AD, and merely 50 ml normal saline in group S or control group just 15 minutes before termination of surgery during 10 minutes. (6) Main outcome measures: when patient is transferred to

postanesthesia care unit (PACU), emergence agitation (EA) using five score (Col et al) criteria, and pain using 10 score TPPPS criteria will be measured and recorded in advent to the recovery room (T0) and in 5,15,30 minutes thereafter and when the patient discharge from PACU. As well as 6 and 24 hours after discharge from PACU the proportion of EA & pain will be measured and recorded in the ward using aforementioned criteria. patient discharge from PACU will be based on Aldrete 10 score criteria. patient with Aldrete score > 9, and when do not have nausea and vomiting, and with controlled EA & pain will be discharged from PACU, and the time of stay in PACU will be recorded.

#### General information

##### Acronym

-

##### IRCT registration information

IRCT registration number: **IRCT2016092930049N1**  
Registration date: **2017-04-12, 1396/01/23**  
Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2017-04-12, 1396/01/23

##### Registrant information

###### Name

Farzad Sarshivi

###### Name of organization / entity

Kurdistan University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 87 3356 1703

**Email address**  
farzadsarshivi@muk.ac.ir

**Recruitment status**  
**Recruitment complete**

**Funding source**  
Vice chancellor for research of Kurdistan University of Medical Sciences

**Expected recruitment start date**  
2017-04-04, 1396/01/15

**Expected recruitment end date**  
2018-04-04, 1397/01/15

**Actual recruitment start date**  
empty

**Actual recruitment end date**  
empty

**Trial completion date**  
empty

**Scientific title**  
Clinical trial Comparison of intravenous dexmedetomidine and intravenous Apotel and combined of those (intravenous Apodex) on postoperative emergence agitation & pain after Adenotonsilectomy with Sevofluran in children

**Public title**  
Effects of intravenous dexmedetomidine and intravenous Apotel and combined of those (intravenous Apodex) on postoperative emergence agitation & pain

**Purpose**  
Prevention

**Inclusion/Exclusion criteria**  
Inclusion criteria: take Informed consent from parents to enter the study; patients between 2-12 old age candidate for Adenotonsilectomy; Physical status 1 and 2 classification of "American Society of Anesthesiologists" (ASA). Exclusion criteria: History of any cardiac, kidney, hepatic, or neurologic (convulsion) disease; Respiratory disease (Asthma or respiratory allergy); History of allergic reaction to the study drugs; History of upper airway infection in the last 4 weeks; use of any type of sedative drugs at the night before surgery; evidence of severe obstructive sleep apnea (OSA)

**Age**  
From **2 years** old to **12 years** old

**Gender**  
Both

**Phase**  
2-3

**Groups that have been masked**  
*No information*

**Sample size**  
Target sample size: **132**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**

**Blinding (investigator's opinion)**  
Double blinded

**Blinding description**

**Placebo**

Used  
**Assignment**  
Parallel  
**Other design features**  
-

## Secondary Ids

1  
**Registry name**  
-  
**Secondary trial Id**  
-  
**Registration date**  
empty

## Ethics committees

1  
**Ethics committee**  
**Name of ethics committee**  
Ethics committee of Kurdistan University of Medical Sciences  
**Street address**  
Pasdaran street, Sanandaj  
**City**  
Sanandaj  
**Postal code**  
**Approval date**  
2016-12-26, 1395/10/06  
**Ethics committee reference number**  
IR.MUK.REC.1395.275

## Health conditions studied

1  
**Description of health condition studied**  
Adenotonsilectomy  
**ICD-10 code**  
J35.3  
**ICD-10 code description**  
Hypertrophy of tonsils with hypertrophy of adenoids

## Primary outcomes

1  
**Description**  
Emergence agitation  
**Timepoint**  
in advent to the recovery room (T0) and in 5,15,30 minutes thereafter and when the patient discharge from PACU. As well as 6 and 24 hours after discharge from PACU  
**Method of measurement**  
five score criteria described by Col for evaluate emergence agitation

## 2

### **Description**

pain

### **Timepoint**

in advent to the recovery room (T0) and in 5,15,30 minutes thereafter and when the patient discharge from PACU. As well as 6 and 24 hours after discharge from PACU

### **Method of measurement**

modified 10 score TPPPS criteria for evaluate of pain in children

## **Secondary outcomes**

### 1

#### **Description**

Delirium

#### **Timepoint**

in advent to the recovery room (T0) and in 5,15,30 minutes thereafter and when the patient discharge from PACU. As well as 6 and 24 hours after discharge from PACU

#### **Method of measurement**

20 score PAED criteria for evaluate delirium in children

### 2

#### **Description**

Time to need the first rescue analgesic dose

#### **Timepoint**

Period of time from PACU admittance until the first need to analgesics

#### **Method of measurement**

By recording period of time between PACU admittance to the first need to analgesics

### 3

#### **Description**

Rate of need to analgesics

#### **Timepoint**

amount of analgesics usage for pain & EA relief

#### **Method of measurement**

By recording of amounts of analgesic usage in PACU & ward

### 4

#### **Description**

Nausea & vomiting

#### **Timepoint**

consideration for beeing Nausea & vomiting

#### **Method of measurement**

Have or not have

### 5

#### **Description**

Time of stay in PACU

#### **Timepoint**

Period of time from admittance to discharge from PACU

### **Method of measurement**

recording period of time from admittance to discharge from PACU based on Aldrete criteria > 9

## **Intervention groups**

### 1

#### **Description**

in group A 15 mg/kg of intravenous acetaminophen in 50 ml normal saline, will be infused 15 minutes before termination of surgery during 10 minutes.

#### **Category**

Treatment - Drugs

### 2

#### **Description**

in group D 1 mcg/kg of intravenous dexmedetomidine in 50 ml normal saline, will be infused 15 minutes before termination of surgery during 10 minutes.

#### **Category**

Treatment - Drugs

### 3

#### **Description**

in group AD 10 mg/kg of intravenous acetaminophen and 0.3 mcg/kg dexmdetomidine in 50 ml normal saline, will be infused 15 minutes before termination of surgery during 10 minutes.

#### **Category**

Treatment - Drugs

### 4

#### **Description**

in group S or control group merely 50 ml normal saline, will be infused 15 minutes before termination of surgery during 10 minutes.

#### **Category**

Placebo

## **Recruitment centers**

### 1

#### **Recruitment center**

##### **Name of recruitment center**

Kosar Hospital of Sanandaj

##### **Full name of responsible person**

Dr.Farzad Sarshivi

##### **Street address**

Kosar hospital, Kurdistan University of Medical Sciences, Pasdaran street, Sanandaj

##### **City**

Sanandaj

## **Sponsors / Funding sources**

## 1

### Sponsor

**Name of organization / entity**

Vice chancellor for research of Kurdistan University of Medical Sciences

**Full name of responsible person**

Dr.Ebrahim Ghaderi

**Street address**

Kurdistan University of Medical Sciences, Pasdaran street, Sanandaj

**City**

Sanandaj

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice chancellor for research of Kurdistan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

*empty*

### Person responsible for general inquiries

**Contact****Name of organization / entity**

Kurdistan University of Medical Sciences

**Full name of responsible person**

Dr.Farzad Sarshivi

**Position**

Anesthesiologist

**Other areas of specialty/work****Street address**

Kurdistan University of Medical Sciences, Pasdaran street, Sanandaj

**City**

Sanandaj

**Postal code****Phone**

+98 87 3356 1356

**Fax****Email**

farzadsarshivi@gmail.com

**Web page address**

### Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Kurdistan University of Medical Sciences

**Full name of responsible person**

Dr.Farzad Sarshivi

**Position**

Anesthesiologist

**Other areas of specialty/work****Street address**

Kurdistan University of Medical Sciences, Pasdaran street, Sanandaj

**City**

Sanandaj

**Postal code****Phone**

+98 87 3356 1356

**Fax****Email**

farzadsarshivi@gmail.com

**Web page address**

### Person responsible for updating data

**Contact****Name of organization / entity**

Kurdistan University of Medical Sciences

**Full name of responsible person**

Dr.Farzad Sarshivi

**Position**

Anesthesiologist

**Other areas of specialty/work****Street address**

Kurdistan University of Medical Sciences, Pasdaran street, Sanandaj

**City**

Sanandaj

**Postal code****Phone**

00

**Fax****Email**

farzadsarshivi@gmail.com

**Web page address**

### Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*